This review of the scientific literature, stretching across six decades, makes the case that antipsychotics, over the long-term, do more harm than good. The drugs lower recovery rates and worsen functional outcomes over longer periods of time.
Jeffrey LIeberman and colleagues have published a paper in the American Journal of Psychiatry stating that there is no evidence that psychiatric drugs cause long-term harm, and that the evidence shows that these drugs provide a great benefit to patients. A close examination of their review reveals that it is a classic example of institutional corruption, which was meant to protect guild interests.
New research counters the long-held assumption that a longer duration of untreated psychosis is associated with worse outcomes.
A new survey exploring antipsychotic user experience finds that more than half of the participants report only negative experiences.
A new systematic review finds that patients report reduced symptoms but also loss of self and agency while taking antipsychotics.
Long-term treatment with antipsychotic drugs is currently considered the standard treatment for patients diagnosed with ‘schizophrenia.’ A new study challenges this practice, however. The...
Study finds that reduced cortical thickness and brain surface area associated with 'schizophrenia' may result from antipsychotic drug use.
A new study has found that of 10 people who were fully recovered from their first episode of schizophrenia (FES), those not taking antipsychotics did better in terms of cognitive, social, and role functioning—and reached full recovery more quickly.
People who take anticholinergic drugs, such as antidepressants and antipsychotics, are at a 50% higher risk of dementia.
A study, recently published in Psychological Medicine, examined the cognitive functioning of individuals with schizophrenia who discontinued antipsychotics, and those who maintained their antipsychotic...
A new study has found that children and adolescents taking a high dose of antipsychotics are almost twice as likely to die of any cause than children on other types of medications.
Researchers reveal the limitations and misleading interpretations of two recent studies that claim to demonstrate that long-term antipsychotic use leads to better outcomes.
The researchers found that while antipsychotic drugs may be slightly more effective than alternative antidepressants, they come with a much higher side effect burden.
A new meta-review examines the experiences of antipsychotic drugs use among people diagnosed with a psychotic disorder.
Common psychotropic medications may be contributing to the higher rates of physical illnesses and mortality in people diagnosed with mental illnesses.
A new study offers radical solutions for improving the cardiovascular health of people with mental health diagnoses: reducing antipsychotic prescriptions..
With increasing evidence that psychiatric drugs do more harm than good over the long term, the field of psychiatry often seems focused on sifting through the mounds of research data it has collected, eager to at last sit up and cry, here’s a shiny speck of gold! Our drugs do work! One recently published study on withdrawal of antipsychotics tells of long-term benefits. A second tells of long-term harm. Which one is convincing?
Dutch researchers write in the Journal of Clinical Psychopharmacology that, in a prospective study of 7415 persons with diagnoses of schizophrenia, use of a first-generation...
A review of the scientific literature related to the withdrawal of antipsychotics: animal studies, withdrawal symptoms, tapering success rates, and consumer accounts of discontinuation.
Study finds that 74% of patients with a psychotic disorder off antipsychotics at end of 10 years are in remission.
Researchers discuss the evidence that antipsychotic medications may cause brain atrophy in children, whose brains are still developing.
New research published in the July issue of The Journal of Clinical Psychiatry found that the use of mood stabilizers, antipsychotics, antidepressants, and hypnotics during pregnancy is associated with increased health risks to the infant.
New research published in the August issue of Psychiatric Annals evaluates the results of randomized control trials on the use of various psychotropic drugs for patients diagnosed with borderline personality disorder (BPD). Despite the “American Psychiatric Association’s practice guidelines endorsement of SSRIs as first-line therapies for BPD,” the results of the meta-analysis reveal that pharmacotherapy in BPD is “not supported by the current literature,” and “should be avoided whenever possible.”
A new analysis of antipsychotic treatment of schizophrenia (published in Schizophrenia Bulletin) has found that two-thirds of patients treated this way do not experience symptom remission.
A new study, published in the Journal of Clinical Psychiatry, investigates the effects of anticholinergic medications, such as antidepressants and antipsychotics, on cognition in older adults diagnosed with schizophrenia.